Clinical Trials Directory

Trials / Not Yet Recruiting

Not Yet RecruitingNCT06750315

CRP /Albumin Ratio and Neutrophil Lymphocyte Ratio in Predicting Activity in IBD Patients

CRP/ Albumin Ratio and Neutrophil Lymphocyte Ratio in Predicting Activity in IBD Patients

Status
Not Yet Recruiting
Phase
Study type
Observational
Enrollment
35 (estimated)
Sponsor
Assiut University · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This study aimed to assess the clinical utility of the NLR (neutrophil lymphocyte ratio) and CRP Albumin ratio in predicting activity of IBD Patients in assiut university

Detailed description

IBD definition term for two conditions (Crohn\'s disease and ulcerative colitis) is a chronic idiopathic inflammatory disease affecting the large intestine. It is characterized by relapsing mucosal inflammation. The aim of treatment is to induce and maintain disease remission. Assessing disease activity may help in optimizing the management of IBD patients. The neutrophil-to-lymphocyte ratio (NLR) is a simple index that can be calculated from the results of ordinary blood tests; it is calculated from a blood sample by dividing the absolute neutrophil count by the absolute lymphocyte count . As the NLR can reflect the systemic status of inflammation or immune response. The underlying mechanism that the NLR was a predictor of clinilcal relapse in UC patients with Mucosal healing remains poorly understood. Neutrophils induce cytotoxicity and inflammation in UC. A high NLR value may be due to high activity in UC and lowered mucosal barrier function, which may lead to the migration of neutrophils through the gut microbiota . CRP is routinely used as a surrogate measure of intestinal inflammation and as a prognostic measure of nonresponse to medical therapy and colectomy in patients with IBD.

Conditions

Timeline

Start date
2025-01-01
Primary completion
2025-10-01
Completion
2025-12-01
First posted
2024-12-27
Last updated
2024-12-27

Locations

2 sites across 1 country: Egypt

Source: ClinicalTrials.gov record NCT06750315. Inclusion in this directory is not an endorsement.